These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3128469)

  • 21. Clinical value of the determination of serum guanase activity. Studies on patients and experimental data from mongrel dogs and cultured rat hepatocytes.
    Ito S; Takaoka T; Nakaya Y; Hiasa Y; Mori H; Tanaka K; Ichihara A
    Gastroenterology; 1982 Nov; 83(5):1102-8. PubMed ID: 6288507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of the determination of serum guanase activity in acute myocardial infarction.
    Ito S; Takaoka T; Kishi S; Sato H; Matsuhisa M; Nakaya Y; Hiasa Y; Murayama Y; Ueda S; Mori H; Murakami T; Kagawa M
    Tokushima J Exp Med; 1978 Jul; 25(1-2):29-35. PubMed ID: 725916
    [No Abstract]   [Full Text] [Related]  

  • 23. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers.
    Barrera JM; Bruguera M; Ercilla MG; Sánchez-Tapias JM; Gil MP; Costa J; Gelabert A; Rodés J; Castillo R
    Ann Intern Med; 1991 Oct; 115(8):596-600. PubMed ID: 1909848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical value of the determination of serum guanase activity in patients with chronic hepatitis type C.
    Matsunaga H; Honda H; Kubo K; Sannomiya K; Cui X; Toyota Y; Mori T; Muguruma N; Okahisa T; Okamura S; Shimizu I; Ito S
    J Med Invest; 2003 Feb; 50(1-2):64-71. PubMed ID: 12630570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation between donor transaminase and recipient hepatitis non-A, non-B in Sweden.
    Widell A; Sundström G; Hansson BG; Fex G; Moestrup T; Nordenfelt E
    Vox Sang; 1988; 54(3):154-9. PubMed ID: 3130727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Screening of blood donors for the prevention of non-A, non-B hepatitis].
    Seidl S
    Dtsch Med Wochenschr; 1983 Jan; 108(4):123-4. PubMed ID: 6402351
    [No Abstract]   [Full Text] [Related]  

  • 27. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis.
    Hoyos M; Sarrión JV; Pérez-Castellanos T; Prieto M; Marty ML; Garrigues V; Berenguer J
    Hepatology; 1989 Mar; 9(3):449-51. PubMed ID: 2493415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum guanase activity in hepatitis C virus infection.
    Shaw T; Li J; Bowden DS; Cooksley G; Locarnini SA
    Adv Exp Med Biol; 1994; 370():475-82. PubMed ID: 7544951
    [No Abstract]   [Full Text] [Related]  

  • 30. [Activity of cobalt-activated acylase and guanase in the serum of patients with viral hepatitis].
    Boroń P; Prokopowicz D; Jarocki F; Ananko J; Lisowski P; Szpakowicz T
    Wiad Lek; 1977 May; 30(10):763-7. PubMed ID: 867992
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical application of serum guanase analysis by electrophoresis].
    Nishikawa Y; Ono N; Fukumoto K; Watanabe F
    Rinsho Byori; 1988 Nov; 36(11):1313-6. PubMed ID: 3249394
    [No Abstract]   [Full Text] [Related]  

  • 32. Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group.
    Blajchman MA; Bull SB; Feinman SV
    Lancet; 1995 Jan; 345(8941):21-5. PubMed ID: 7528310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and experimental studies of the determination of serum guanase activity in acute myocardial infarction.
    Ito S; Takaoka T; Kishi S; Nakaya Y; Hiasa Y; Mori H
    Jpn Circ J; 1981 May; 45(5):525-31. PubMed ID: 7230507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.
    Stevens CE; Aach RD; Hollinger FB; Mosley JW; Szmuness W; Kahn R; Werch J; Edwards V
    Ann Intern Med; 1984 Dec; 101(6):733-8. PubMed ID: 6437308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of post-transfusion non-A, non-B hepatitis].
    Habibi B; Smilovici W
    Rev Fr Transfus Immunohematol; 1988 Oct; 31(3):537-86. PubMed ID: 3144032
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.
    Sugg U; Schenzle D; Hess G
    Transfusion; 1988; 28(4):386-8. PubMed ID: 3133848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infectivity of blood seropositive for hepatitis C virus antibodies.
    van der Poel CL; Reesink HW; Schaasberg W; Leentvaar-Kuypers A; Bakker E; Exel-Oehlers PJ; Lelie PN
    Lancet; 1990 Mar; 335(8689):558-60. PubMed ID: 1968574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transfusion non-A, non-B hepatitis: significance of raised ALT and anti-HBc in blood donors.
    Biswas R
    Vox Sang; 1989; 56(1):63. PubMed ID: 2492703
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical and laboratory-based evaluation of serum guanase activity in liver diseases].
    Matsumoto K; Sugiuchi H; Yamane N; Sagara K
    Rinsho Byori; 1986 Sep; 34(9):1059-64. PubMed ID: 3795539
    [No Abstract]   [Full Text] [Related]  

  • 40. A review of recent events related to surrogate testing of blood to prevent non-A, non-B posttransfusion hepatitis.
    Zuck TF; Sherwood WC; Bove JR
    Transfusion; 1987; 27(2):203-6. PubMed ID: 3103271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.